Literature DB >> 10483587

Thymic tumours in Denmark. A retrospective study of 213 cases from 1970-1993.

P Engel1, A Marx, H K Müller-Hermelink.   

Abstract

Histological slides of 213 thymic tumours were reviewed twice and classified according to Kirchner and Müller-Hermelink into 122 thymomas (syn. organotypic thymic epithelial tumours (TET)), 58 thymic carcinomas (syn. non-organotypic TET) and 16 lymphomas. Tumour heterogeneity (i.e. features of two subtypes in one tumour) appeared in 38% of the organotypic TET. The overall diagnostic correspondence between the reviews of the 122 organotypic TET was 48%. By reducing the five diagnostic groups to three: organotypic TET benign (medullary and mixed thymomas), organotypic TET low-grade (organoid and cortical thymomas and well-differentiated thymic carcinoma (WDTC)) and non-organotypic TET (usually high-grade thymic carcinomas), and minimising the effect of tumour heterogeneity in this way, the diagnostic correspondence increased to 82%. Correlating histological type with stage, we found that 80% of medullary and 87% of mixed thymomas were stage I, that 85% of cortical and 81% of WDTC were stage II or III, and that non-organotypic TET were stage II or III (86%) or stage IV (14%), respectively. It is suggested to report on the heterogeneity of a given case of thymic epithelial tumour in the pathology reports and give the approximate percentage of each component, telling the clinician which component may determine the prognosis.

Entities:  

Mesh:

Year:  1999        PMID: 10483587     DOI: 10.1016/S0344-0338(99)80006-5

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  4 in total

Review 1.  A typical thymic carcinoid tumour within a thymolipoma: report of a case and review of combined tumours of the thymus.

Authors:  Christina Steger; Hans-Joerg Steiner; Katharina Moser; Heinrich Fiechtl; Patrizia Moser; Thomas Schmid; Ralf Joachim Rieker
Journal:  BMJ Case Rep       Date:  2010-11-02

Review 2.  Key components of chemotherapy for thymic malignancies: a systematic review and pooled analysis for anthracycline-, carboplatin- or cisplatin-based chemotherapy.

Authors:  Yusuke Okuma; Makoto Saito; Yukio Hosomi; Toshikazu Sakuyama; Tatsuru Okamura
Journal:  J Cancer Res Clin Oncol       Date:  2014-08-22       Impact factor: 4.553

3.  Chemoradiotherapy for unresectable cases of thymic epithelial tumors: a retrospective study.

Authors:  Jumpei Kashima; Yusuke Okuma; Hiroto Murata; Kageaki Watanabe; Yukio Hosomi; Tsunekazu Hishima
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

Review 4.  [Standard outcome measures for thymic malignancies].

Authors:  James Huang; Frank C Detterbeck; Zuoheng Wang; Patrick J Loehrer
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2014-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.